Conditional replication of oncolytic viruses based on detection of oncogenic mRNA

Area of Science:

• Biotechnology
• Oncology
• Molecular Biology

Background:

• Split intein-based sensors offer modular targeting of specific RNA sequences.
• Identifying earliest-occurring (truncal) mutations in cancer is crucial for effective treatment strategies.
• Developing targeted cancer therapies requires effective delivery vectors and mechanisms.

Purpose of the Study:

• To propose a novel cancer detection and treatment strategy leveraging split intein sensors and a modified viral vector.
• To outline a method for identifying and targeting truncal mutations in multi-region cancer sequencing.
• To conceptualize a sense-and-respond therapeutic system for eradicating tumors and metastases.

Main Methods:

• Utilizing multi-region, multi-sample sequencing to identify truncal oncogenic mutations.
• Employing split intein-based sensors to detect these specific mutations.
• Designing a hyper-virulent herpes simplex virus as a potential delivery vector.
• Implementing concurrent immunosuppression to facilitate tumor infection by the viral vector.
• Exogenous small molecule-mediated enhancement of viral replication within tumor cells.
• Inducing a targeted toxin with a bystander effect for cancer cell destruction.

Main Results:

• The proposed strategy enables precise identification of early cancer mutations.
• Split intein sensors can be engineered to act as "sense-and-respond" modules.
• A modified herpes simplex virus vector, combined with immunosuppression, could effectively target tumors.
• Oncogenic mutations can be leveraged as "kindling" for targeted viral replication.
• The system aims for complete cancer eradication through induced toxicity and bystander effects.

Conclusions:

• This integrated approach offers a potential new paradigm for personalized cancer therapy.
• The combination of advanced RNA detection and targeted viral delivery holds promise for treating disseminated cancers.
• Further research and development are warranted to validate this innovative sense-and-respond therapeutic strategy.